MiPLA: Difference between revisions

Line 4:

MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for [[LSD]]. It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University. MiPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".<ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf</ref><ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebookc_searchable.pdf</ref> According to Shulgin, human subjects administered MIPLA at doses of 180–300μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.<ref>Halberstadt, A.L., Klein, L.M., Chatha, M. et al. Psychopharmacology (2018). http://dx.doi.org/10.1007/s00213-018-5055-9</ref>

User reports describe the effects of MiPLA as similar to those of LSD, with some marked differences. It is described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides.

User reports describe the effects of MiPLA as similar to those of LSD, with some marked differences. It is described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides. Reports of users taking up to 600ug doses have indicated that higher doses of MiPLA don't change the experience very much if at all, whether visually, mentally, or physically.

Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. It is highly advised to use harm reduction practices when using this substance.

@@ Line 4: / Line 4: @@
 MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for [[LSD]]. It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University. MiPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".<ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf</ref><ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebookc_searchable.pdf</ref> According to Shulgin, human subjects administered MIPLA at doses of 180–300μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.<ref>Halberstadt, A.L., Klein, L.M., Chatha, M. et al. Psychopharmacology (2018). http://dx.doi.org/10.1007/s00213-018-5055-9</ref>
-User reports describe the effects of MiPLA as similar to those of LSD, with some marked differences. It is described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides.
+User reports describe the effects of MiPLA as similar to those of LSD, with some marked differences. It is described as being more mentally and physically oriented but with a less introspective headspace and subtle, albeit pronounced visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than other lysergamides. Reports of users taking up to 600ug doses have indicated that higher doses of MiPLA don't change the experience very much if at all, whether visually, mentally, or physically.
 Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. It is highly advised to use harm reduction practices when using this substance.